 |
|
Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
Byung-Cheol Song, Yoo-Kyung Cho, Hyeyoung Jwa, Eun Kwang Choi, Heung Up Kim, Hyun Joo Song, Soo-Young Na, Sun-Jin Boo, Seung Uk Jeong
Clin Mol Hepatol. 2014;20(4):355-360. Published online 2014 Dec 24 DOI: https://doi.org/10.3350/cmh.2014.20.4.355
|
|
Citations to this article as recorded by
 Replication and Expression of the Consensus Genome of Hepatitis B Virus Genotype C from the Chinese Population
Fenfang Liao, Junmou Xie, Rongsong Du, Wenbo Gao, Lanyin Lan, Min Wang, Xia Rong, Yongshui Fu, Hao Wang
Viruses.2023; 15(12): 2302. CrossRef KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee
Clinical and Molecular Hepatology.2020; 26(4): 411. CrossRef 2018 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis B: What's Different?
Ji Hoon Kim
The Korean Journal of Gastroenterology.2019; 73(3): 132. CrossRef KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2019; 25(2): 93. CrossRef Natural History and Treatment Indications of Chronic Hepatitis B
Dong Hyun Sinn
The Korean Journal of Gastroenterology.2019; 74(5): 245. CrossRef Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend
Grace Lai-Hung Wong
Clinical and Molecular Hepatology.2018; 24(2): 108. CrossRef
|